G9020 – Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
HCPCS Level II code · G codes: Procedures / Professional Services (Temporary)
HCPCS codeG9020
- Long description
- Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
- Short description
- Rimantadine hcl 100mg oral
- Pricing indicator
13Priced by the Medicare contractor (carrier)- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- Added
- December 1, 2004
- Last change
- January 1, 2020 – No change
- Termination date
- December 31, 2019
Frequently asked questions
What is HCPCS code G9020?
G9020 is a HCPCS Level II code for rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project). It was discontinued on December 31, 2019.
Does Medicare cover G9020?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby G codes
- G9011 – Coordinated care fee, risk adjusted maintenance, level 5
- G9012 – Other specified case management service not elsewhere classified
- G9013 – Esrd demo basic bundle level i
- G9014 – Esrd demo expanded bundle including venous access and related services
- G9016 – Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]
- G9017 – Amantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
- G9018 – Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
- G9019 – Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)
- G9033 – Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)
- G9034 – Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)
- G9035 – Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)
- G9036 – Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
- G9037 – Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health care professional for the care of the patient (i.e. not for professional education or scheduling) and may include subsequent follow up on the specialist's recommendations; 30 minutes
- G9038 – Co-management services with the following elements: new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care planning; condition for which specialist is taking a co-management role; condition expected to last at least 3 months; comprehensive care plan established, implemented, revised or monitored in partnership with co-managing clinicians; ongoing communication and care coordination between co-managing clinicians furnishing care
- G9050 – Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)
- G9051 – Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a medicare-approved demonstration project)
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.